Literature DB >> 15702041

Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.

Dan M Granoff1, Amy Morgan, Jo Anne Welsch.   

Abstract

BACKGROUND: An investigational quadrivalent (A, C, Y and W-135) meningococcal conjugate (MC-4) vaccine was reported to be more immunogenic in 2-year-olds than the currently licensed meningococcal polysaccharide vaccine, but persistence of serum antibody beyond 6 months after conjugate vaccination is unknown.
OBJECTIVE: Determine persistence and the immunologic basis of protective activity of group C anticapsular antibodies in sera obtained 2-3 years after MC-4 vaccination.
DESIGN: Group C antibody concentrations, bactericidal activity and passive protective activity were measured in sera from 48 children, ages 4-5 years, who had been immunized 2-3 years earlier with an MC-4 vaccine and from 47 children who had not been previously vaccinated.
RESULTS: Serum antibody concentrations were higher in the vaccinated than the unvaccinated children (geometric means, 0.30 and 0.09 mug/mL, respectively, P < 0.0001). Bactericidal titers > or =1/4 (considered protective) were infrequent in both vaccinated and unvaccinated children (14.6 and 6.4%, respectively, P = 0.3). Passive protective activity against bacteremia in the infant rat model was more frequent in sera from vaccinated (37.5%) than sera from unvaccinated children (12.5%, P < 0.02). The proportion of sera with passive protective activity increased with increasing anticapsular antibody concentrations (P < 0.0001).
INTERPRETATION: Serum group C antibody concentrations remained elevated for 2-3 years after MC-4 vaccination, and passive protective activity was more frequent in vaccinated than unvaccinated children. However, serum antibody concentrations in many vaccinated children were no longer sufficient to activate complement-mediated bacteriolysis in vitro or to confer passive protection against experimental group C disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15702041      PMCID: PMC1413970          DOI: 10.1097/01.inf.0000151035.64356.f8

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  27 in total

1.  Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.

Authors:  M E Ramsay; N Andrews; E B Kaczmarski; E Miller
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

2.  Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.

Authors:  P Richmond; R Borrow; E Miller; S Clark; F Sadler; A Fox; N Begg; R Morris; K Cartwright
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

3.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.

Authors:  A Leach; P A Twumasi; S Kumah; W S Banya; S Jaffar; B D Forrest; D M Granoff; D E LiButti; G M Carlone; L B Pais; C V Broome; B M Greenwood
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

5.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

6.  Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.

Authors:  J MacLennan; S Obaro; J Deeks; D Lake; C Elie; G Carlone; E R Moxon; B Greenwood
Journal:  J Infect Dis       Date:  2000-11-15       Impact factor: 5.226

7.  Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood.

Authors:  J MacLennan; S Obaro; J Deeks; D Williams; L Pais; G Carlone; R Moxon; B Greenwood
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

8.  Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

Authors:  D Goldblatt; A R Vaz; E Miller
Journal:  J Infect Dis       Date:  1998-04       Impact factor: 5.226

9.  Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.

Authors:  N E MacDonald; S A Halperin; B J Law; B Forrest; L E Danzig; D M Granoff
Journal:  JAMA       Date:  1998-11-18       Impact factor: 56.272

Review 10.  Complement deficiency states and meningococcal disease.

Authors:  J Figueroa; J Andreoni; P Densen
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

View more
  11 in total

1.  The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci.

Authors:  Lisa A Lewis; Matthew Carter; Sanjay Ram
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

2.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 3.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

Review 5.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

6.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 7.  Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.

Authors:  David Pace; Andrew J Pollard
Journal:  Arch Dis Child       Date:  2007-10       Impact factor: 3.791

Review 8.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

Review 9.  Bacterial meningitis: the impact of vaccination.

Authors:  Nick Makwana; F Andrew I Riordan
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.